New research from Mount Sinai in New York has found that orthopedic surgeons performing shoulder arthroplasty may want to consider tranexamic acid (TXA).
The research, “Utilization and Real-World Effectiveness of Tranexamic Use In Shoulder Arthroplasty: A Population-Based Study,” was presented at the recent meeting of the American Academy of Orthopaedic Surgeons in New Orleans.
Shawn G. Anthony, M.D., M.B.A., assistant professor of orthopedics at the Icahn School of Medicine at Mount Sinai and shoulder and sports medicine surgeon at Mount Sinai West, told OTW, “We are seeking to maximize safety of shoulder arthroplasty in our patients.”
“Blood loss requiring transfusion is less common than in total knee or total shoulder but still required in some patients. We utilized the Premier Perspective database that includes approximately 20% of all shoulder arthroplasties performed in U.S. We chose 2010-2016 to analyze current TXA utilization in available, complete datasets.”
The authors wrote, “Overall, TXA was used in 5.2% (n=2,636) of patients with a strong increasing trend. After adjustment for relevant covariates, TXA use (compared to no TXA use) was associated with a 38% decrease in transfusion risk (OR 0.62 CI 0.46-0.84 P<0.05) and a 45% decreased risk for combined complications (OR 0.55 CI 0.33-0.90 P<0.05). Moreover, TXA use was associated with 8.0% shorter length of hospital stay (CI -10.0%;-5.8% P<0.05) while no difference was observed for cost of hospitalization.”
Dr. Anthony told OTW, “While utilization of TXA has become very common in total hip and knee arthroplasty, TXA is still used in less than 50% of patients undergoing shoulder arthroplasty as of 2016. Utilization is increasing but continued education is important. The use of TXA presents one more way to improve the safety of shoulder arthroplasty for patients.”
